期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 69, 期 8, 页码 1519-1534出版社
SPRINGER
DOI: 10.1007/s00262-020-02560-5
关键词
Resected non-small cell lung cancer; Positron emission tomography; Tumor immunometabolic phenotypes; Tumor glycolysis
资金
- Lung SPORE [5 P50 CA070907] Funding Source: Medline
- NCI NIH HHS [R01 CA187076, P50 CA221703, P50 CA070907, R01 CA184845, P30 CA016672] Funding Source: Medline
- Cancer Prevention and Research Institute of Texa [RP170401] Funding Source: Medline
- MD Anderson Cancer Center Support Grant [P30CA01667] Funding Source: Medline
- Conquer Cancer Foundation (ASCO 2018 Career Development Award) [12895] Funding Source: Medline
- Khalifa Bin Zayed Al Nahyan Foundation [Khalifa Scholar Award] Funding Source: Medline
- DoD PROSPECT Grant [W81XWH-07-1-0306] Funding Source: Medline
Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are of considerable clinical interest. In this study, we characterized the relationships among tumor(18)F-fluorodeoxyglucose (FDG) retention, tumor metabolic and immune phenotypes, and survival in patients with resected non-small cell lung cancer (NSCLC). We retrospectively analyzed tumor preoperative positron emission tomography (PET)F-18-FDG uptake in 59 resected NSCLCs and investigated correlations between PET parameters (SUVMax, SUVTotal, SUVMean, TLG), tumor expression of glycolysis- and immune-related genes, and tumor-associated immune cell densities that were quantified by immunohistochemistry. Tumor glycolysis-associated immune gene signatures were analyzed for associations with survival outcomes. We found that each(18)F-FDG PET parameter was positively correlated with tumor expression of glycolysis-related genes. Elevated(18)F-FDG SUV(Max)was more discriminatory of glycolysis-associated changes in tumor immune phenotypes than other(18)F-FDG PET parameters. Increased SUV(Max)was associated with multiple immune factors characteristic of an immunosuppressive and poorly immune infiltrated tumor microenvironment, including elevated PD-L1 expression, reduced CD57(+)cell density, and increased T cell exhaustion gene signature. Elevated SUV(Max)identified immune-related transcriptomic signatures that were associated with enhanced tumor glycolytic gene expression and poor clinical outcomes. Our results suggest that(18)F-FDG SUV(Max)has potential value as a noninvasive, clinical indicator of tumor immunometabolic phenotypes in patients with resectable NSCLC and warrants investigation as a potential predictor of therapeutic response to immune-based treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据